ImmunityBio (IBRX) Extends Gains to 10th Day on 700% Anktiva Sales Jump; Time to Book Profits?

We recently published 10 Stock With Eye-Popping Gains; 5 Are on Fresh Highs. ImmunityBio Inc. (NASDAQ:IBRX) was one of the top performers on Thursday.

ImmunityBio extended its winning streak to a 10th consecutive day on Thursday, soaring 30.79 percent to close at $3.95 apiece, as investors loaded portfolios after achieving a 700 percent jump in preliminary revenues from Anktiva for the full-year 2025.

During the period, ImmunityBio Inc. (NASDAQ:IBRX) said that it registered $113 million in revenues from Anktiva amid strong demand. Anktiva is the first FDA-approved immunotherapy for non-muscle invasive bladder cancer.

In the fourth quarter alone, ImmunityBio Inc. (NASDAQ:IBRX) posted $38.3 million in net revenues, marking a 431 percent increase from the same period last year.

ImmunityBio (IBRX) Extends Gains to 10th Day on 700% Anktiva Sales Jump; Time to Book Profits?

“ImmunityBio continues to see increased sales momentum supporting a trend of increases quarter-over-quarter with a 54 percent quarter over quarter unit volume growth rate during FY 2025,” it said.

In other recent news, ImmunityBio Inc. (NASDAQ:IBRX) has secured the approval of the Saudi Food and Drug Administration to sell and market Anktiva, in combination with an immune checkpoint inhibitor, in Saudi Arabia.

“This approval represents a significant step forward for lung cancer patients in the Kingdom of Saudi Arabia and a meaningful milestone that we hope will pave the way toward additional approvals across a region where lung cancer claims far too many lives each year,” said Executive Chairman Patrick Soon-Shiong.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.